Case report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis
Lichen amyloidosis (LA) is a predominant type of primary cutaneous amyloidosis that is characterized by persistent and intense skin itching. Although multiple therapeutics strategies are available for its treatment, there is no standard treatment so far. Abrocitinib, an oral small-molecule Janus kin...
Saved in:
| Main Authors: | Yizhen Zhang, Dawei Huang, Yunlu Gao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1477664/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New-onset psoriasis with abrocitinib therapy for atopic dermatitis
by: Sarah L. Becker, BA, et al.
Published: (2025-07-01) -
Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report
by: Zhaoyang Wang, et al.
Published: (2025-12-01) -
Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis
by: Song D, et al.
Published: (2025-04-01) -
The impact of abrocitinib treatment on lesion area and pruritus in patients with atopic dermatitis: a systematic review and meta-analysis
by: Xiao-Li Kou, et al.
Published: (2025-07-01) -
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
by: Jonathan I. Silverberg, et al.
Published: (2025-02-01)